Make a ppt of 25 slides on topic hypertensive disorders in pregnancy mainly pre-eclampsia definitions detailed etiopathogenesis prediction of pre eclampsia prevention of pre-eclampsia clinical features investigation and it's management
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
Reading File
Running Command
Running Command
Writing File
Running Command
Running Command
Your presentation is ready! Download it here:
Hypertensive Disorders Pregnancy PE
Presentation · PPTX
What's Inside – 25 Slides
The deck uses a professional navy blue / teal / gold palette on a wide (16:9) layout. Here is the full slide map:
| # | Slide | Content |
|---|---|---|
| 1 | Title Slide | Hypertensive Disorders in Pregnancy – dark navy with sky-blue accent |
| 2 | Lecture Outline | 10-section agenda in two columns |
| 3 | Section Divider | Classification & Definitions |
| 4 | Classification Table | All 6 disorders – definition, onset (gestational HTN, PE, eclampsia, chronic HTN, superimposed PE, white-coat HTN) |
| 5 | Diagnostic Criteria | ISSHP/ACOG 2018 criteria – essential + additional (proteinuria, renal, hepatic, haematological, neurological, uteroplacental) |
| 6 | Section Divider | Epidemiology & Risk Factors |
| 7 | Epidemiology | Global burden (4.6% PE; 10–12% HTN in pregnancy; 30% maternal deaths in LMICs) + high-risk groups |
| 8 | Risk Factors | Two-column: maternal/obstetric vs comorbidities + paternal factors |
| 9 | Section Divider | Etiopathogenesis |
| 10 | Two-Stage Model | Stage 1 (placental - spiral artery failure) → Stage 2 (maternal systemic endothelial injury) |
| 11 | Molecular Mechanisms | sFlt-1/PlGF angiogenic imbalance, sEng, NK cells, oxidative stress, NF-κB, genetic polymorphisms |
| 12 | Spiral Artery Remodeling | Normal vs defective trophoblast invasion side-by-side comparison |
| 13 | Section Divider | Prediction |
| 14 | First-Trimester Screening | FMF combined algorithm (UtA-PI + MAP + PAPP-A + PlGF); detection rates; sFlt-1/PlGF ratio for 2nd/3rd trimester |
| 15 | Section Divider | Prevention |
| 16 | Prevention | LDA (ASPRE trial data); calcium supplementation; pre-conception optimisation; folic acid |
| 17 | Section Divider | Clinical Features |
| 18 | Clinical Features | Symptoms vs signs in two columns (oedema, headache, visual changes, hyperreflexia, oliguria, FGR) |
| 19 | Section Divider | Investigations |
| 20 | Investigations Table | Renal, haematological, hepatic, metabolic, CV, biomarkers (PlGF/sFlt-1), Doppler, neuroimaging |
| 21 | Section Divider | Management |
| 22 | Antihypertensive Drugs Table | Labetalol, nifedipine, methyldopa, hydralazine, MgSO₄; contraindicated drugs (ACEi/ARBs) |
| 23 | General Management & Delivery | BP targets, fluid restriction, steroids, MgSO₄, timing of delivery by gestational age |
| 24 | HELLP & Eclampsia | HELLP criteria (Tennessee/Mississippi), MgSO₄ protocol for eclampsia, calcium gluconate antidote |
| 25 | Key Takeaways | 10 evidence-based summary points |
This is a shared conversation. Sign in to Orris to start your own chat.